CJC-1295 Side Effects: A Research Guide

Research reference · Updated September 2026 · ~6 min read

CJC-1295 is a growth hormone releasing hormone (GHRH) analog studied for its effect on natural growth hormone output. This overview covers the side effects reported in research and community use. It is research information only.

Why side effects happen

Because CJC-1295 works by increasing growth hormone release, most reported effects trace back to that mechanism rather than direct toxicity. When growth hormone and the downstream hormone IGF-1 rise, the body can show predictable responses.

Commonly reported effects

Blend note: CJC-1295 is often studied with ipamorelin. When effects appear in a stack it can be hard to attribute them to one peptide. See the CJC-1295 and ipamorelin dosage guide for how the pair is structured.

Dose dependence

Effects such as water retention and tingling are more often reported at higher doses. Following the ranges on the CJC-1295 protocol page and measuring accurately helps keep exposure steady. Sourcing tested material from the supplier list removes contaminant driven effects.

What is not established

Long term human safety and effects on those with hormone sensitive conditions are unknown. Sustained elevation of growth hormone and IGF-1 is a theoretical concern that has not been fully characterized in people, which reinforces the research only status.

Source tested CJC-1295

View the Supplier List →
⚠️ RESEARCH USE ONLY: This content is for educational and research purposes only. Peptides discussed are not approved for human consumption. Nothing here is medical advice. Consult qualified professionals.